Summary
Eli Lilly and Company (LLY) filed an 8-K on May 4, 2017, to disclose the execution of an Underwriting Agreement for a significant debt offering. The company issued and sold $2.25 billion in aggregate principal amount of senior notes across three tranches: $750 million of 2.350% Notes due 2022, $750 million of 3.100% Notes due 2027, and $750 million of 3.950% Notes due 2047. This debt issuance is expected to provide the company with approximately $2.2 billion in net proceeds after accounting for underwriter discounts but before offering expenses, indicating a strategic move to bolster its financial resources. The proceeds from this offering are intended to support the company's ongoing operations and strategic initiatives. Investors should note the maturity dates and coupon rates of these notes, which represent a long-term debt commitment for Lilly. The company has outlined provisions for potential early redemption and remedies in case of default, as detailed in the Indenture and related agreements.
Key Highlights
- 1Eli Lilly priced a debt offering totaling $2.25 billion across three tranches of notes.
- 2The notes issued include $750 million of 2.350% Notes due 2022.
- 3The notes issued include $750 million of 3.100% Notes due 2027.
- 4The notes issued include $750 million of 3.950% Notes due 2047.
- 5The company expects to receive approximately $2.2 billion in net proceeds from the offering.
- 6The debt issuance matures on May 15, 2022, May 15, 2027, and May 15, 2047, respectively.
- 7The offering was registered on a Form S-3 and closed on May 9, 2017.